Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Urology · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 83.3%Moderate 0 · 0%High 0 · 0%

Blue light vs white light

Time to recurrence · patients with non‐muscle invasive bladder cancer

Blue light may leads to lower time to disease recurrence (absolute event rates based on 12 months compared with white light (low certainty).

1 finding from 1 review

Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
HR 0.66 [0.54, 0.81]
15 studies · 2994 participants
Low

Blue light vs white light

Time to progression · patients with non‐muscle invasive bladder cancer

Blue light may leads to lower time to disease progression (absolute event rates based on 12 months compared with white light (low certainty).

1 finding from 1 review

Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
HR 0.65 [0.5, 0.84]
9 studies · 2200 participants
Low

Blue light vs white light

Surgical complications, serious (up to 90 days; MCID 2%) · patients with non‐muscle invasive bladder cancer

Blue light showed no clear difference in surgical complications, serious (up to 90 days; MCID 2%) compared with white light (low certainty).

1 finding from 1 review

Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
RR 0.54 [0.14, 2.14]
1 study · 525 participants
Low

Blue light vs white light

Time to death from bladder cancer · patients with non‐muscle invasive bladder cancer

Blue light showed no clear difference in time to death from bladder cancer (absolute event rates based on 60… compared with white light (low certainty).

1 finding from 1 review

Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
HR 0.55 [0.19, 1.61]
1 study · 407 participants
Low

Blue light vs white light

Any adverse events (up to 90 days; MCID 5%) · patients with non‐muscle invasive bladder cancer

Blue light showed no clear difference in any adverse events (up to 90 days; MCID 5%) compared with white light (low certainty).

1 finding from 1 review

Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
RR 1.09 [0.88, 1.33]
3 studies · 1375 participants
Low

Blue light vs white light

Surgical complications, non‐serious (up to 90 days; MCID 5%) · patients with non‐muscle invasive bladder cancer

The review found no eligible studies for this question.

1 finding from 1 review

Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found